The 60 references in paper I. Malyshev Yu., S. Lyamina V., Sh. Shimshelashvili L., E. Vasserman N., И. Малышев Ю., С. Лямина В., Ш. Шимшелашвили Л., Е. Вассерман Н. (2014) “Функциональные ответы альвеолярных макрофагов, сурфактантный белок D и заболевания легких // Functions of alveolar macrophages and surfactant protein D in lung disease” / spz:neicon:pulmonology:y:2011:i:3:p:101-107

1
Чучалин А.Г.(ред.). Стандарты по диагностике и лечению больных хронической обструктивной болезнью легких (ATS / ERS, пересмотр 2004 г.). Пер. с англ. М.: Атмосфера; 2005.
(check this in PDF content)
2
Хаитов Р.М.Иммунология: Учебник. М.: ГЭОТАР-Медиа; 2006.
(check this in PDF content)
3
Janeway C.A., Travers P., Walport M., Shlomchik M. Immunobiology. The immune system in health and disease: New York: Garland Science Publishing, 2005.
(check this in PDF content)
4
Mantovani A., Sica A., Sozzani S. et al.The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25: 677–686.
(check this in PDF content)
5
Mantovani A.Macrophage diversity and polarization: in vivo veritas. Blood 2006; 108 (2): 408–409.
(check this in PDF content)
6
Mantovani A., Sica A., Locatti A. New vistas on macrophage differentiation and activation. Eur. J. Immunol. 2006; 37 (1): 14–16.
(check this in PDF content)
7
Boehm U., Klamp T., Groot M., Howard J.C.Cellular responses to interferon-gamma. Ann. Rev. Immunol. 1997; 15: 749–795.
(check this in PDF content)
8
Sharma M. Chemokines and their receptors: orchestrating a fine balance between health and disease. Crit. Rev. Biotechnol. 2010; 30: 1–22.
(check this in PDF content)
9
Trost M., English L., Limieux S. et al. The phagosomal proteome in interferon-?-activated macrophages. Immunity 2009; 30 (1): 143–154.
(check this in PDF content)
10
Nelson S.Novel nonantibiotic therapies for pneumonia. Cytokines and host defence. Chest 2001; 119 (2): 419S–425S.
(check this in PDF content)
11
Martinez F.O., Gordon S., Locati A., Mantovani A.Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: New molecules and patterns of gene expression. J. Immunol. 2006; 177: 7303–7311.
(check this in PDF content)
12
Kaplan A.P.Chemokines, chemokine receptors and allergy. Int. Arch. Allergy Immunol. 2001; 124 (4): 423–431.
(check this in PDF content)
13
Falcone F.H., Haas H., Gibbs B.F.The human basophil: a new appreciation of its role in immune responses. Blood 2000; 96 (13): 4028–4038.
(check this in PDF content)
14
D'Andrea A., Aste5Amezaga M., Valiante N.M. et al. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor / IL-12 synthesis in accessory cells. J. Exp. Med. 1993; 178 (3): 1041–1048.
(check this in PDF content)
15
Hu S., Sheng W.S., Peterson P.K., Chao C.C. Differential regulation by cytokines of production of nitric oxide by human astrocytes. Glia 1995; 15: 491–494.
(check this in PDF content)
16
Gordon S. The macrophage: Past, present and future. Eur. J. Immunol. 2007; 37: S9.
(check this in PDF content)
17
Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front. Biosci. 2008; 1 (13): 453–461.
(check this in PDF content)
18
Sieling P.A., Abrams J.S., Yamamura M. et al. Immunosuppressive roles for IL-10 and IL-4 in human infection. In vitro modulation of T cell responses in leprosy. J. Immunol.
(check this in PDF content)
19
3; 150 (12): 5501–5510. 19.Oosterhout A.J.M., Motta A.C.Th1 / Th2 paradigm: not seeing the forest for the trees? Eur. Respir. J. 2005; 25: 591–593.
(check this in PDF content)
20
Mantovani A., Sozzani S., Locati M. et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002; 23 (11): 549–555.
(check this in PDF content)
21
Fritz J., Murphy B.S., Sundareshan V. et al.M1 and M2 Macrophage activation. Azithromycin alters macrophage phenotype. J. Antimicrob. Chemother. 2008; 61 (3): 554–560.
(check this in PDF content)
22
Atochina E.N., Beck J.M., Scanlon S.T. et al. Pneumocystis carinii pneumonia alters expression and distribution of lung collectins SP-A and SP-D. J. Lab. Clin. Med. 2001; 137: 429–39.
(check this in PDF content)
23
Atochina E.N., Beers M.F., Hawgood S. et al. Surfactant protein-D, a mediator of innate lung immunity, alters the products of nitric oxide metabolism. Am. J. Respir. Cell Mol. Biol. 2004; 30: 271–279.
(check this in PDF content)
24
Cheng G., Ueda T., Numao T. et al. Increased levels of surfactant protein A and D in bronchoalveolar lavage fluids in patients with bronchial asthma. Eur. Respir. J. 2000; 16: 831–835.
(check this in PDF content)
25
Cheng I.W., Ware L.B., Greene K.E. et al.Prognostic value of surfactant proteins A and D in patients with acute lung injury. Crit. Care Med. 2003; 31: 20–27.
(check this in PDF content)
26
Eisner M.D., Parsons P., Matthay M.A. et al. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax 2003; 58: 983–988.
(check this in PDF content)
27
Fujita M., Shannon J.M., Ouchi H. et al.Serum surfactant protein D is increased in acute and chronic inflammation in mice. Cytokine 2005; 31: 25–33.
(check this in PDF content)
28
Kuan S., Rust K., Crouch E. Interactions of surfactant protein D with bacterial lipopolysaccharides. J. Clin. Invest. 1992; 90: 97–106.
(check this in PDF content)
29
Wright J.R. Immunomodulatory functions of surfactant. Physiol. Rev. 1997; 77: 931–962.
(check this in PDF content)
30
Crouch E.C.Structure, biologic properties and expression of surfactant protein D. Biochim. Biophys. Acta 1998; 1408: 278–289.
(check this in PDF content)
31
Sorensen G.L., Husby S., Holmskov U. Surfactant protein A and surfactant protein D variation in pulmonary disease. Immunobiology 2007; 212 (4–5): 381–416. Обзоры
(check this in PDF content)
32
Sin D.D., Pahlavan P.S., Man P.S.P. Surfactant protein D: A lung specific biomarker in COPD?: Potential biological roles of SP-D in COPD. Ther. Adv. Respir Dis. 2008; 2 (2): 65–74.
(check this in PDF content)
33
Fisher J.H., Larson J., Cool C., Dow S.W. Lymphocyte activation in the lungs of SP-D null mice. Am. J. Respir. Cell. Mol. Biol. 2002; 27: 24–33.
(check this in PDF content)
34
Botas C.F., Poulain J., Akiyama J. et al. Altered surfactant homeostasis and alveolar type II cell morphology in mice lacking surfactant protein D. Proc. Natl. Acad. Sci. USA 1998; 95:11869–11874.
(check this in PDF content)
35
Wert S.E., Yoshida M., LeVine A.M. et al. Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc. Natl. Acad. Sci. USA 1997; 97: 5972–5977.
(check this in PDF content)
36
Korfhagen T.R., Sheftelyevich V., Burhans M.S. et al. Surfactant protein-D regulates surfactant phospholipid homeostasis in vivo. J. Biol. Chem. 1998; 273: 28438–28443.
(check this in PDF content)
37
Yoshida M., Korfhagen Th.R., Whitsett J.A.Surfactant protein D regulates NF-κB and matrix metalloproteinase production in alveolar macrophages via oxidant-sensitive pathways. J. Immunol. 2001; 166: 7514–7519.
(check this in PDF content)
38
LeVine A.M., Whitsett J.A., Gwozdz J.A. et al.Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J. Immunol. 2000; 165: 3934–3940.
(check this in PDF content)
39
Gardai S.J., Xiao Y.5Q., Dickinson M. et al.By binding SIRP-alpha or calreticulin / CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 2003; 115: 13–23.
(check this in PDF content)
40
Atochina5Vasserman E.N., Kadire H., Tomer Y. et al. Selective inhibition of iNOS activity in vivo reverses inflammatory abnormalities in SP-D deficient mice. J. Immunol. 2007; 179 (12): 8090–8097.
(check this in PDF content)
41
Atochina5Vasserman E.N., Abramova E.V., Tomer Y. et al. SP-D-Dependent regulation of NO metabolism in lipopolysaccharide-stimulated peritoneal macrophages. Bull. Exp. Biol. Med. 2009; 147 (4): 415–420.
(check this in PDF content)
42
Sano H., Kuroki Y.The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. Mol. Immunol. 2005; 42 (3): 279–287.
(check this in PDF content)
43
Guo C.J., Atochina5Vasserman E.N., Abramova H. et al. S-Nitrosylation of surfactant protein-D controls inflammatory function. PLoS Biol. 2008; 6 (11): e266.
(check this in PDF content)
44
Zhang L., Ikegami M., Crouch E.C. et al. Activity of pulmonary surfactant protein-D (SP-D) in vivo is dependent on oligomeric structure. J. Biol. Chem. 2001; 276 (22): 19214–19219.
(check this in PDF content)
45
Guo C.J., Rashman C.S., Wolf B.A., Gow A.J. S-Nitrosylation of surfactant protein-D provides a molecular switch from anti- to pro-inflammatory function. Nitric Oxide 2006; 14 (4): 6.
(check this in PDF content)
46
McCormack F.X., Whitsett J.A. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J. Clin. Invest 2002; 109 (6): 707–712.
(check this in PDF content)
47
Bartlett J.G., Breiman R.F., Mandell L.A. et al. Communityacquired pneumonia in adults-guidelines for management. Clin. Infect. Dis. 1998; 26: 811–838.
(check this in PDF content)
48
Bufler P., Schikor D., Schmidt B., Griese M.Cytokine stimulation by Pseudomonas aeruginosa strain variation and modulation by pulmonary surfactant. Exp. Lung Res. 2004; 30 (3): 163–179.
(check this in PDF content)
49
Lofdahl M., Wahlstorm J., Skold C.M. Different inflammatory cell pattern and macrophage phenotype in chronic obstructive pulmonary disease patients, smokers and nonsmokers. Clin. Exp. Immunol. 2006; 145 (3): 428–437.
(check this in PDF content)
50
Pons A.R., Noguera A., Blanquer D. et al.Phenotypic characterization of alveolar macrophages and peripheral blood monocytes in COPD. Eur. Respir. J. 2005; 25 (4): 647–652.
(check this in PDF content)
51
Shaykhiev R., Krause A., Salit J. et al. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J. Immunol. 2009; 183: 2867–2883.
(check this in PDF content)
52
Лещенко И.В.Глобальная инициатива по хронической обструктивной болезни легких: новые направления в лечении. Урал. мед. Журн. 2006; 8 (36).
(check this in PDF content)
53
Sethi S., Maloney J., Grove L. et al.Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Res. Med. COPD Update 2006; 1 (4): 144–145.
(check this in PDF content)
54
Доклад экспертов ВОЗ; 2005.
(check this in PDF content)
55
Woodruff P.G., Modrek B., Choy D.F. et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am. J. Respir. Crit. Care Med. 2009; 180 (5): 388–395.
(check this in PDF content)
56
Шмелев Е.И. Дифференциальная диагностика интерстициальных заболеваний легких. Consilium Medicum 2003; 5 (4): 176–181.
(check this in PDF content)
57
Kunitake R., Kuwano K., Yoshida K. et al. KL-6, surfactant protein A and D in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Respiration 2001; 68: 488–495.
(check this in PDF content)
58
Kucejko W., Chyczewska E., Naumnik W., Ossolinska M. Concentration of surfactant protein D, Clara cell protein CC-16 and IL-10 in bronchoalveolar lavage (BAL) in patients with sarcoidosis, hypersensivity pneumonitis and idiopathic pulmonary fibrosis. Folia Histochem. Cytobiol. 2009; 47 (2): 225–230.
(check this in PDF content)
59
Zissel G., Prasse A., Muller5Quernheim J. Sarcoidosisimmunopathogenetic concepts. J. Semin. Respir. Crit. Care Med. 2007; 28 (1): 3–14.
(check this in PDF content)
60
Prasse A., Georges C.G., Biller H. et al.Тh1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+and CD8+T cells. Clin. Exp. Immunol. 2000; 122 (2): 241–248. Информация об авторах Малышев Игорь Юрьевич – д. м. н., проф., зав. лабораторией клеточ-
(check this in PDF content)